According to a report by CNN, the U.S. Food and Drug Administration (FDA) has granted priority review designation to global pharmaceutical and biotechnology company Pfizer (PFE) and BioNTech SE’s (BNTX) application for full approval of their COVID-19 vaccine. BioNTech is a German biotechnology firm that makes immunotherapies for autoimmune disorders, allergies, infectious diseases and cancer. The FDA is likely to reach a decision on the vaccine’s full approval within two months. The companies started filing Biologics License Application for full approval in May. They are seeking to get the vaccine approved for people at least 16 years of age.
https://www.tipranks.com/news/pfizer-biontechs-covid-19-vaccine-application-gets-priority-review-status-report?utm_source=advfn.com&utm_medium=referral
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more BioNTech Charts.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more BioNTech Charts.